A Phase 2a, Multi-Center, Randomized, Parallel Group, Double Blind and Placebo-controlled Clinical Trial to Assess Safety and Tolerability as Well as Explorative Efficacy of the Orthosteric Selective Muscarinic M1 Agonist NSC001 in Mild to Moderate Alzheimer's Disease
Latest Information Update: 04 Jun 2025
At a glance
- Drugs NGX 267 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
Most Recent Events
- 04 Jun 2025 New trial record